Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.

@article{Murray2007AntiretroviralTW,
  title={Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.},
  author={John M. Murray and Sean Emery and Anthony D. Kelleher and Matthew G. Law and Joshua Chen and Daria Hazuda and Bach-Yen T Nguyen and Hedy Teppler and David A. Cooper},
  journal={AIDS},
  year={2007},
  volume={21 17},
  pages={2315-21}
}
OBJECTIVE Raltegravir (MK-0518) belongs to the new class of HIV integrase inhibitors. To date, there have been no reports investigating the potential for differential effects on viral dynamics with integrase inhibitors relative to current antiretroviral drugs. METHODS Patients in this phase II study (P004) were antiretroviral treatment naive. Part 1 of this study compared monotherapy with raltegravir (100 mg, 200 mg, 400 mg, or 600 mg twice daily) with placebo over 10 days. In part 2… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 83 extracted citations

Similar Papers

Loading similar papers…